Drugs / Zagotenemab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03019536 | Jan 2017 → Jun 2019 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02754830 | Apr 2016 → Jul 2018 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03518073 | Apr 2018 → Aug 2021 | Alzheimer disease | Eli Lilly and Company | Completed | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zagotenemab | “Zagotenemab (LY3303560), a monoclonal antibody” PMID 37849628 ↗ Sep 2023 |
| Known as | LY3303560 | “Zagotenemab (LY3303560), a monoclonal antibody that preferentially targets misfolded, extracellular, aggregated tau, was assessed in the PERISCOPE-ALZ phase 2 study” PMID 38386949 ↗ Feb 2024 |
| Action | Inhibit | “Microtubule-associated protein tau inhibitor” CHEMBL4298021 ↗ |
| Modality | Monoclonal antibody | “a monoclonal antibody” PMID 37849628 ↗ Sep 2023 |
| Route | Intravenous | “administered intravenously (IV)” NCT02754830 ↗ |
| Target | MAPT | “Microtubule-associated protein tau inhibitor” CHEMBL4298021 ↗ |